Core Viewpoint - Zimmer Biomet Holdings, Inc. (ZBH) is set to report its fourth-quarter 2025 results on February 10, with expectations of revenue growth and earnings per share (EPS) increase compared to the previous year [1][9]. Group 1: Financial Estimates - The Zacks Consensus Estimate for ZBH's revenues is $2.20 billion, reflecting an 8.9% increase from the same quarter last year [2]. - The consensus estimate for earnings is $2.38 per share, indicating a 3% rise from the year-ago figure [2]. - The bottom-line estimate has remained unchanged over the past 30 days [2]. Group 2: Business Segment Performance - The Hips business is expected to grow due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated HAMMR surgical impactor [3][4]. - The total Hips business is projected to report a 10.5% year-over-year growth [5]. - The Knees business is likely to benefit from the increasing adoption of the Persona OsseoTi cementless total knee system, with an expected 7.5% year-over-year growth [6]. - The S.E.T business is anticipated to continue its growth trend, with expectations of mid-single-digit growth for the seventh consecutive quarter [7]. - New product launches in the foot and ankle trauma portfolio, such as the Gorilla Pilon Fusion Plating system, may positively impact fourth-quarter performance [8]. Group 3: Recent Developments - Zimmer Biomet received PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System, which may enhance top-line performance [5]. - The acquisition of Paragon 28, Inc. and the CE Mark certification for the RibFix Advantage Fixation System are expected to contribute positively to the company's performance [10]. - The company completed the acquisition of Monogram Technologies Inc., an AI-driven orthopedic robotics firm, which may also have a favorable impact on fourth-quarter results [12]. Group 4: Growth Projections - The Technology & Data, Bone Cement, and Surgical business is estimated to report a 6.5% year-over-year growth for the quarter [13]. - The total S.E.T. business is projected to achieve a 13% year-over-year growth [10].

Core Viewpoint - Investors in the Chemical - Specialty sector should consider Novozymes A/S (NVZMY) and Hawkins (HWKN) for potential value opportunities, with NVZMY currently appearing to offer better value based on various financial metrics [1]. Valuation Metrics - Novozymes A/S has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Hawkins, which has a Zacks Rank of 3 (Hold) [3]. - NVZMY has a forward P/E ratio of 24.53, while HWKN has a higher forward P/E of 31.23, suggesting that NVZMY may be undervalued relative to HWKN [5]. - The PEG ratio for NVZMY is 1.11, compared to HWKN's PEG ratio of 1.95, indicating that NVZMY has a more favorable earnings growth outlook relative to its valuation [5]. - NVZMY's P/B ratio is 2.26, significantly lower than HWKN's P/B ratio of 5.04, further supporting the argument that NVZMY is a better value option [6]. - Based on these metrics, NVZMY has earned a Value grade of B, while HWKN has a Value grade of C, reinforcing the perception of NVZMY as the superior value stock [6]. Earnings Outlook - Novozymes A/S is noted for its improving earnings outlook, which enhances its attractiveness in the current market [7].

Core Viewpoint - Investors in the Diversified Communication Services sector should consider Deutsche Telekom AG (DTEGY) and PT Telekomunikasi (TLK) for potential value opportunities [1] Group 1: Zacks Rank and Earnings Outlook - Deutsche Telekom AG has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to PT Telekomunikasi, which has a Zacks Rank of 3 (Hold) [3] - The improving earnings outlook for DTEGY makes it a more attractive option in the current market [7] Group 2: Valuation Metrics - DTEGY has a forward P/E ratio of 12.75, while TLK has a forward P/E of 13.58, suggesting DTEGY may be undervalued [5] - The PEG ratio for DTEGY is 1.24, compared to TLK's PEG ratio of 2.85, indicating DTEGY's expected earnings growth is more favorable [5] - DTEGY's P/B ratio is 1.55, while TLK's P/B ratio is 2.23, further supporting DTEGY's valuation advantage [6] Group 3: Value Grades - Based on various valuation metrics, DTEGY holds a Value grade of A, whereas TLK has a Value grade of C, highlighting DTEGY's superior value proposition [6]

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) is expected to report its fourth-quarter 2025 results on February 4, with a history of exceeding earnings estimates in the previous four quarters, averaging an 11.11% surprise [1][2]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for GEHC's fourth-quarter 2025 revenues is $5.59 billion, reflecting a 5.2% increase from the prior-year quarter [2]. - The consensus estimate for adjusted earnings per share (EPS) is $1.43, indicating a 1.4% decrease from the prior-year period [2]. Performance Drivers - GE HealthCare's fourth-quarter performance is anticipated to be steady, driven by strong customer demand, a favorable capital equipment environment, and traction from recent product launches [3]. - Organic revenue growth is expected to remain robust, with strong execution across Imaging, Advanced Visualization Solutions (AVS), and Pharmaceutical Diagnostics, despite margin pressures from tariffs and investment spending [3][4]. Segment Analysis Imaging - Revenue growth in the Imaging segment is supported by strong demand in the U.S. and EMEA markets, with customers upgrading aging diagnostic imaging equipment [5]. - Order trends remained strong, bolstered by large system deals and a healthy capital spending backdrop, although margins faced headwinds from tariffs [5][6]. Advanced Visualization Solutions - The AVS segment is likely to show solid performance, driven by strong adoption of AI-enabled ultrasound and image-guided solutions, contributing to above-average revenue growth [7][8]. Patient Care Solutions - The Patient Care Solutions segment is expected to have softer performance due to a temporary product hold that constrained shipments, although improvements are anticipated following the resolution of this issue [9]. Pharmaceutical Diagnostics - The Pharmaceutical Diagnostics segment is projected to deliver strong results, driven by growth in contrast media and radiopharmaceuticals, despite some margin pressure from planned investments and integration costs [10]. Margin and EPS Outlook - GE HealthCare's margins and EPS are expected to show sequential improvement, supported by volume recovery in Patient Care Solutions and continued productivity actions, despite ongoing tariff-related headwinds [11]. Share Price Performance - Over the past six months, GE HealthCare's shares have increased by 13.4%, outperforming the industry, which saw a 9.6% decline, and the S&P 500, which gained 13.1% during the same period [14].

Core Insights - The Zacks Industrial Products sector is expected to face a year-over-year earnings decline of 2.1% in Q4 2025, contrasting with a 3% growth in the previous quarter, while revenues are projected to increase by 10.5% [3] Industry Overview - The Industrial Products sector is experiencing challenges due to ongoing weakness in the manufacturing sector, with the Manufacturing PMI indicating contraction for ten consecutive months [5] - The New Orders Index has also shown a decline, with readings of 48.7%, 47.3%, and 47.4% for October, November, and December respectively [6] - Inflationary pressures, labor market slack, supply-chain disruptions, and cautious consumer spending are impacting the sector's performance [7] Positive Factors - Companies involved in commercial and defense aerospace markets are benefiting from strong aftermarket and OEM demand, supported by robust air travel and government backing [8] - Resilience in nondurables, business supplies, and food & beverage markets is expected to positively influence the sector's results [8] Earnings Estimates and Stock Performance - Kennametal Inc. (KMT) is projected to report a 40% year-over-year increase in Q4 EPS, driven by strength in the Metal Cutting segment and increased defense spending [12][13] - Mueller Water Products, Inc. (MWA) is expected to see an 8% year-over-year increase in earnings, supported by solid demand across its product lines and manufacturing efficiencies [14][15] - Trimble Inc. (TRMB) anticipates a 7.9% year-over-year increase in earnings, benefiting from strong growth in recurring revenue streams and customer adoption of digital solutions [16][17]

Core Viewpoint - Xcel Energy (XEL) is expected to report its fourth-quarter 2025 results on February 5, with a consensus earnings per share (EPS) estimate of 97 cents, reflecting a year-over-year increase of 19.75% and revenues projected at $3.73 billion, indicating a 19.44% increase from the previous year [1][5][8]. Factors Impacting Earnings - The anticipated earnings growth for Xcel Energy is attributed to an increase in demand from its expanding electric and natural gas customer base, supported by investments in new service centers across Minnesota [2][8]. - Positive outcomes from regulatory proceedings, including authorization to defer incremental insurance costs related to wildfire risks and recovery of operations and maintenance costs associated with wildfire mitigation, are expected to contribute positively to earnings [3][8]. Cost Considerations - Despite the positive factors, rising operation and maintenance expenses, along with increased property taxes and interest expenses, are likely to offset some of the earnings gains in the fourth quarter [4][8]. Earnings Expectations - The Zacks Consensus Estimate for Xcel Energy's EPS is set at 97 cents, which represents a year-over-year increase of 19.75%, while the revenue estimate stands at $3.73 billion, reflecting a 19.44% increase from the previous year [5][8]. Earnings Prediction Model - The current earnings prediction model indicates that Xcel Energy does not have a strong likelihood of beating earnings expectations, as it has an Earnings ESP of -1.37% and a Zacks Rank of 3 (Hold) [6][7].

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Assurant (AIZ) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 10, might help the stock move higher if these key numbers are better than expecta ...

Core Viewpoint - The market anticipates American International Group (AIG) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - AIG is expected to report quarterly earnings of $1.89 per share, reflecting a year-over-year increase of +45.4% [3]. - Revenues are projected to be $7.1 billion, which is a 3.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.31% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for AIG is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.39%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - AIG currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, AIG exceeded the expected earnings of $1.68 per share by delivering $2.20, resulting in a surprise of +30.95% [13]. - Over the past four quarters, AIG has consistently beaten consensus EPS estimates [14]. Conclusion - AIG is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors influencing stock performance ahead of the earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Mirion Technologies, Inc. despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Mirion Technologies is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year decrease of 5.9% [3]. - Revenue projections stand at $281.82 million, indicating a 10.8% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 3.03% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Mirion is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.41% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [9][10]. - Mirion Technologies currently holds a Zacks Rank of 3, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Mirion exceeded the expected earnings of $0.11 per share by delivering $0.12, resulting in a surprise of +9.09% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Context - In the Zacks Technology Services industry, Gen Digital is expected to report earnings of $0.63 per share, reflecting a year-over-year increase of 12.5% [18]. - Gen Digital's revenue is projected at $1.23 billion, up 24.4% from the previous year, with an unchanged consensus EPS estimate but a lower Most Accurate Estimate leading to an Earnings ESP of -0.40% [19][20].